FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282012105> ?p ?o ?g. }

• W4282012105 endingPage "5040" @default.
• W4282012105 startingPage "5040" @default.
• W4282012105 abstract "5040 Background: 223 Ra and 177 Lu-PSMA both prolong overall survival (OS) in different mCRPC settings. Previous data from the observational REASSURE (Sartor O, et al. 2021) and WARMTH (Ahmadzadehfar H, et al. 2021) studies suggested the feasibility of sequencing 223 Ra and 177 Lu-PSMA therapies. Here we used data from the observational, retrospective RALU study to further examine the safety and clinical outcomes of sequential 223 Ra/ 177 Lu-PSMA therapy in pts with mCRPC. Methods: This interim analysis investigated the baseline characteristics, safety (primary endpoint) and OS (secondary endpoint) in pts who received 177 Lu-PSMA after 223 Ra using retrospective data collected in German centers. Results: Data from 49 pts were available for this interim analysis. At baseline, before the start of 177 Lu-PSMA, 73% of pts were Eastern Cooperative Oncology Group performance status (ECOG PS) 1 and 27% ECOG PS 2. Visceral metastases were present in 31% of pts. Median prostate-specific antigen (PSA) and alkaline phosphatase (ALP) were 287 ng/ml and 142 U/L, respectively (Table). 70% of pts received ≥4 life-prolonging therapies prior to 177 Lu-PSMA, with abiraterone acetate (80%), enzalutamide (67%) and docetaxel (92%) being the most frequently used. 74% of pts received ≥5 223 Ra injections. Pts received either PSMA-617 (67%) or PSMA I&T (33%): 65% of pts received 1–4 cycles and 33% received 5–6 cycles. Median duration of 177 Lu-PSMA therapy was 4.9 months (m) (0–57.1). Median time from the last 223 Ra dose to first 177 Lu-PSMA dose was 9.3 m (0.9–41.9). Any grade treatment-emergent adverse events (TEAEs) from the start of 177 Lu-PSMA therapy to 30 days of follow-up occurred in 91.8% of pts, and serious TEAEs in 20% of pts. Grade 3-4 hematologic laboratory abnormalities up to 90 days post- 177 Lu-PSMA occurred in 34.7% of pts for anemia, 12.8% for thrombocytopenia and 2.0% for neutropenia. No grade 5 toxicities occurred. 39% of pts had ≥30% decline in PSA during 177 Lu-PSMA treatment. Median OS was 12.6 m (95% CI 8.8–16.1) from the start of 177 Lu-PSMA therapy. Conclusions: In this real-world retrospective analysis of selected pts with advanced mCRPC, the 223 Ra/ 177 Lu-PSMA treatment sequence was clinically feasible and well tolerated. [Table: see text]" @default.
• W4282012105 created "2022-06-13" @default.
• W4282012105 creator A5002020225 @default.
• W4282012105 creator A5004144764 @default.
• W4282012105 creator A5004503139 @default.
• W4282012105 creator A5006572675 @default.
• W4282012105 creator A5016440729 @default.
• W4282012105 creator A5024581793 @default.
• W4282012105 creator A5025657000 @default.
• W4282012105 creator A5032460328 @default.
• W4282012105 creator A5033712600 @default.
• W4282012105 creator A5044417330 @default.
• W4282012105 creator A5053681162 @default.
• W4282012105 creator A5062424480 @default.
• W4282012105 creator A5062907808 @default.
• W4282012105 creator A5067941796 @default.
• W4282012105 creator A5075105680 @default.
• W4282012105 date "2022-06-01" @default.
• W4282012105 modified "2023-10-06" @default.
• W4282012105 title "Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–prostate-specific membrane antigen (¹⁷⁷Lu-PSMA) after radium-223 (²²³Ra): Interim analysis of the RALU study." @default.
• W4282012105 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.5040" @default.
• W4282012105 hasPublicationYear "2022" @default.
• W4282012105 type Work @default.
• W4282012105 citedByCount "1" @default.
• W4282012105 countsByYear W42820121052022 @default.
• W4282012105 crossrefType "journal-article" @default.
• W4282012105 hasAuthorship W4282012105A5002020225 @default.
• W4282012105 hasAuthorship W4282012105A5004144764 @default.
• W4282012105 hasAuthorship W4282012105A5004503139 @default.
• W4282012105 hasAuthorship W4282012105A5006572675 @default.
• W4282012105 hasAuthorship W4282012105A5016440729 @default.
• W4282012105 hasAuthorship W4282012105A5024581793 @default.
• W4282012105 hasAuthorship W4282012105A5025657000 @default.
• W4282012105 hasAuthorship W4282012105A5032460328 @default.
• W4282012105 hasAuthorship W4282012105A5033712600 @default.
• W4282012105 hasAuthorship W4282012105A5044417330 @default.
• W4282012105 hasAuthorship W4282012105A5053681162 @default.
• W4282012105 hasAuthorship W4282012105A5062424480 @default.
• W4282012105 hasAuthorship W4282012105A5062907808 @default.
• W4282012105 hasAuthorship W4282012105A5067941796 @default.
• W4282012105 hasAuthorship W4282012105A5075105680 @default.
• W4282012105 hasConcept C121608353 @default.
• W4282012105 hasConcept C126322002 @default.
• W4282012105 hasConcept C126894567 @default.
• W4282012105 hasConcept C143998085 @default.
• W4282012105 hasConcept C203092338 @default.
• W4282012105 hasConcept C2775832370 @default.
• W4282012105 hasConcept C2776551883 @default.
• W4282012105 hasConcept C2777783956 @default.
• W4282012105 hasConcept C2777899217 @default.
• W4282012105 hasConcept C2780192828 @default.
• W4282012105 hasConcept C2780737065 @default.
• W4282012105 hasConcept C2781190966 @default.
• W4282012105 hasConcept C2781406297 @default.
• W4282012105 hasConcept C535046627 @default.
• W4282012105 hasConcept C61367390 @default.
• W4282012105 hasConcept C61943457 @default.
• W4282012105 hasConcept C71924100 @default.
• W4282012105 hasConceptScore W4282012105C121608353 @default.
• W4282012105 hasConceptScore W4282012105C126322002 @default.
• W4282012105 hasConceptScore W4282012105C126894567 @default.
• W4282012105 hasConceptScore W4282012105C143998085 @default.
• W4282012105 hasConceptScore W4282012105C203092338 @default.
• W4282012105 hasConceptScore W4282012105C2775832370 @default.
• W4282012105 hasConceptScore W4282012105C2776551883 @default.
• W4282012105 hasConceptScore W4282012105C2777783956 @default.
• W4282012105 hasConceptScore W4282012105C2777899217 @default.
• W4282012105 hasConceptScore W4282012105C2780192828 @default.
• W4282012105 hasConceptScore W4282012105C2780737065 @default.
• W4282012105 hasConceptScore W4282012105C2781190966 @default.
• W4282012105 hasConceptScore W4282012105C2781406297 @default.
• W4282012105 hasConceptScore W4282012105C535046627 @default.
• W4282012105 hasConceptScore W4282012105C61367390 @default.
• W4282012105 hasConceptScore W4282012105C61943457 @default.
• W4282012105 hasConceptScore W4282012105C71924100 @default.
• W4282012105 hasIssue "16_suppl" @default.
• W4282012105 hasLocation W42820121051 @default.
• W4282012105 hasOpenAccess W4282012105 @default.
• W4282012105 hasPrimaryLocation W42820121051 @default.
• W4282012105 hasRelatedWork W122177069 @default.
• W4282012105 hasRelatedWork W1980998207 @default.
• W4282012105 hasRelatedWork W2568045406 @default.
• W4282012105 hasRelatedWork W2768013934 @default.
• W4282012105 hasRelatedWork W2768688864 @default.
• W4282012105 hasRelatedWork W2770702948 @default.
• W4282012105 hasRelatedWork W2808859772 @default.
• W4282012105 hasRelatedWork W2879638111 @default.
• W4282012105 hasRelatedWork W2935971723 @default.
• W4282012105 hasRelatedWork W4282012105 @default.
• W4282012105 hasVolume "40" @default.
• W4282012105 isParatext "false" @default.
• W4282012105 isRetracted "false" @default.
• W4282012105 workType "article" @default.